Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol
A Sarnelli, ML Belli, V Di Iorio, E Mezzenga, M Celli… - Molecules, 2019 - mdpi.com
Radio-ligand therapy (RLT) with177Lu-PSMA-617 is a promising option for patients with
metastatic castration-resistant prostate-cancer (mCRPC). A prospective phase-II study …
metastatic castration-resistant prostate-cancer (mCRPC). A prospective phase-II study …
Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
J Kemppainen, A Kangasmäki, S Malaspina, B Pape… - Cancers, 2022 - mdpi.com
Simple Summary The optimal treatment regimen with 177Lu-PSMA-617 for metastatic
castration-resistant prostate cancer patients is not known. In this retrospective analysis, the …
castration-resistant prostate cancer patients is not known. In this retrospective analysis, the …
Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant …
K Fizazi, K Herrmann, BJ Krause, K Rahbar… - The Lancet …, 2023 - thelancet.com
Background In VISION, the prostate-specific membrane antigen (PSMA)-targeted
radioligand therapy lutetium-177 [177 Lu] Lu-PSMA-617 (vipivotide tetraxetan) improved …
radioligand therapy lutetium-177 [177 Lu] Lu-PSMA-617 (vipivotide tetraxetan) improved …
Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
N Mader, C Schoeler, N Pezeshkpour, K Klimek… - Cancers, 2023 - mdpi.com
Simple Summary Radioligand therapy (RLT) usually consists of predefined cycles of 177Lu-
PSMA-617 every 6–8 weeks. Although side-effects of RLT are considered well tolerable …
PSMA-617 every 6–8 weeks. Although side-effects of RLT are considered well tolerable …
177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
The aim of this narrative review is to evaluate the current status of 177Lu-PSMA (prostate
specific membrane antigen) therapy for metastatic castration-resistant prostate cancer …
specific membrane antigen) therapy for metastatic castration-resistant prostate cancer …
Efficacy and safety of Ac-225 PSMA radio ligand therapy in metastatic prostate cancer. A systematic review and metanalysis
Abstract Background: Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in
metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225 …
metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225 …
225Ac-PSMA-617 for therapy of prostate cancer
C Kratochwil, U Haberkorn, FL Giesel - Seminars in nuclear medicine, 2020 - Elsevier
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-
emitting 177 Lutetium has already been investigated in several early phase dosimetry …
emitting 177 Lutetium has already been investigated in several early phase dosimetry …
177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
Purpose Lutetium-177 prostate-specific membrane antigen-617 (177 Lu-PSMA-617) in end-
stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable …
stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable …
External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies
J Kurth, BJ Krause, SM Schwarzenböck, L Stegger… - EJNMMI research, 2018 - Springer
Background Prostate-specific membrane antigen (PSMA)-targeted therapy with 177 Lu-
PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate …
PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate …
Where to next for theranostics in prostate cancer?
DG Murphy, N Sathianathen… - European …, 2019 - euoncology.europeanurology.com
The role of molecular imaging using small-molecule ligands labelled with 68Ga or 18F that
bind to prostate-specific membrane antigen (PSMA) continues to be defined for men …
bind to prostate-specific membrane antigen (PSMA) continues to be defined for men …